DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 205874/S-004

SUPPLEMENT APPROVAL

Keryx Biopharmaceuticals, Inc.
Attention: Helen Milton
Vice President, Global Regulatory Affairs
One Marina Park Drive, 10th Floor
Boston, MA 02210

Dear Dr. Milton:

Please refer to your Supplemental New Drug Application (sNDA) dated January 6, 2015, received, January 6, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Auryxia (ferric citrate) Tablets.

We acknowledge receipt of your amendment dated April 30, 2015.

This "Prior Approval" supplemental new drug application provides for revisions to the **DRUG INTERACTIONS** and **CLINICAL PHARMACOLOGY, Pharmacokinetics,** *Drug Interactions Studies* sections of the labeling.

Please note the addition of the following paragraph to the **NON CLINICAL TOXICOLOGY**, **Carcinogenesis, Mutagenesis, and Impairment of Fertility** section of the labeling:

> The potential for ferric citrate to impair reproductive performance or to cause fetal malformation has not been evaluated. Skeletal and encephalic malformation was observed in neonatal mice when ferric gluconate was administered intraperitoneally to gravid dams on gestation days 7-9. However, oral administration of other ferric or ferrous compounds to gravid CD1-mice and Wistar-rats caused no fetal malformation.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the

addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Brian Proctor, Regulatory Project Manager, at (240) 240-3596.

Sincerely,

{See appended electronic signature page}

Norman L. Stockbridge M.D., Ph.D.
Division Director
Center for Drug Evaluation and Research
Division of Cardiovascular and Renal Products

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NORMAN L STOCKBRIDGE
07/21/2015